% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ceccon:885860,
      author       = {Ceccon, G. and Lohmann, Philipp and Werner, Jan-Michael and
                      Caroline, Tscherpel and Dunkl, Veronika and Stoffels,
                      Gabriele and Rosen, Jurij and Rapp, Marion and Herrlinger,
                      Ulrich and Schäfer, Niklas and Shah, N. J. and Fink, Gereon
                      Rudolf and Langen, Karl-Josef and Galldiks, Norbert},
      title        = {{E}arly treatment response assessment using
                      $^{18}${F}-{FET} {PET} compared to contrast-enhanced {MRI}
                      in glioma patients after adjuvant temozolomide chemotherapy},
      journal      = {Journal of nuclear medicine},
      volume       = {62},
      number       = {7},
      issn         = {0022-3123},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {FZJ-2020-04140},
      pages        = {918-925},
      year         = {2021},
      abstract     = {The goal of this study was to compare the value of
                      contrast-enhanced MRI and O-(2-[18F]fluoroethyl)-l-tyrosine
                      (18F-FET) PET for response assessment in glioma patients
                      after adjuvant temozolomide chemotherapy (TMZ). Methods:
                      After biopsy or resection and completion of radiotherapy
                      with concomitant TMZ, 41 newly diagnosed and
                      histomolecularly characterized glioma patients
                      (glioblastoma, $90\%;$ age range, 20–79 y) were
                      subsequently treated with adjuvant TMZ. MR and 18F-FET PET
                      imaging were performed at baseline and after the second
                      cycle of adjuvant TMZ. We obtained 18F-FET metabolic tumor
                      volumes (MTVs) as well as mean and maximum tumor-to-brain
                      ratios (TBRmean and TBRmax, respectively). Threshold values
                      of 18F-FET PET parameters to predict outcome were
                      established by receiver-operating-characteristic analyses
                      using a median progression-free survival (PFS) of ≥ 9 mo
                      and overall survival (OS) of ≥ 15 mo as reference. MRI
                      response assessment was based on the Response Assessment in
                      Neuro-Oncology (RANO) working group criteria. The predictive
                      value of changes of 18F-FET PET and MRI parameters on
                      survival was evaluated subsequently using univariate and
                      multivariate survival estimates. Results: After 2 cycles of
                      adjuvant TMZ chemotherapy, a treatment-induced reduction of
                      MTV and TBRmax predicted a significantly longer PFS and OS
                      (both P ≤ 0.03; univariate survival analyses) whereas RANO
                      criteria were not significant (P > 0.05). Multivariate
                      survival analysis revealed that TBRmax changes predicted a
                      prolonged PFS (P = 0.012) and changes of MTV a prolonged OS
                      (P = 0.005) independent of
                      O6-methylguanine-DNA-methyltransferase promoter methylation
                      and other strong prognostic factors. Conclusion: Changes of
                      18F-FET PET parameters appear to be helpful for identifying
                      responders to adjuvant TMZ early after treatment
                      initiation.},
      cin          = {INM-3 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572) / 5253 -
                      Neuroimaging (POF4-525)},
      pid          = {G:(DE-HGF)POF3-572 / G:(DE-HGF)POF4-5253},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33158907},
      UT           = {WOS:000709477900011},
      doi          = {10.2967/jnumed.120.254243},
      url          = {https://juser.fz-juelich.de/record/885860},
}